BiotechTubeBiotechTube
Home/United Therapeutics/Dr. David Nagle
DD

Dr. David Nagle

Chief Technology Officer

United Therapeutics

Therapeutic Areas

Pulmonary Arterial HypertensionRare DiseasesPulmonary HypertensionGene TherapyXenotransplantation

United Therapeutics Pipeline

DrugIndicationPhase
Treprostinil (Remodulin)Pulmonary Arterial HypertensionCommercial
Treprostinil (Tyvaso)PAH and PH-ILDCommercial
Treprostinil (Orenitram)Pulmonary Arterial HypertensionCommercial
Selexipag (Uptravi)Pulmonary Arterial HypertensionCommercial
RalinepagPulmonary Arterial HypertensionPhase 3
Aurora-GTAADC DeficiencyPhase 1/2
Xenotransplant ProgramOrgan TransplantationPre-clinical
RemUnity PumpPAH Drug DeliveryDevelopment

Leadership Team at United Therapeutics

DM
Dr. Martine Rothblatt
Chairman and Chief Executive Officer
MB
Michael Benkowitz
President and Chief Operating Officer
JE
James Edgemond
Chief Financial Officer
DL
Dr. Leigh Peterson
Chief Medical Officer
PM
Paul McCudden
Chief Commercial Officer
DC
Dr. Christopher Paige
Executive Vice President, Research and Development
View full United Therapeutics profile